US · 2 sources covering this

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year Business live – latest updates GSK’s new boss, Luke Miels , has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two late-stage medications. The FTSE 100 company is increasing its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech company that develops cancer drugs, including three for l…

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

2 L · 0 C · 0 R

How 2 sources are covering this

The GuardianLean L·2h ago
GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm
Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year Business live – latest updates GSK’s new boss, Luke Miels , has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two late-stage medications. The FTSE 100 company is increasing its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech company that develops cancer drugs, including three for l…
Read at The Guardian →
The GuardianLean L

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/4a8fea71edc7609cc071e4abb49e04913f1c991b"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm"></iframe>

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

How 2 sources are covering this